Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

46 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Chronic Plasma Exposure to Kinase Inhibitors in Patients with Oncogene-Addicted Non-Small Cell Lung Cancer.
Geraud A, Mezquita L, Auclin E, Combarel D, Delahousse J, Gougis P, Massard C, Jovelet C, Caramella C, Adam J, Naltet C, Lavaud P, Gazzah A, Lacroix L, Rouleau E, Vasseur D, Mir O, Planchard D, Paci A, Besse B. Geraud A, et al. Among authors: gougis p. Cancers (Basel). 2020 Dec 14;12(12):3758. doi: 10.3390/cancers12123758. Cancers (Basel). 2020. PMID: 33327482 Free PMC article.
Nilotinib versus imatinib for GIST.
Gougis P, Paci A, Coriat R, Urien S, Mir O. Gougis P, et al. Lancet Oncol. 2015 Jul;16(7):e311. doi: 10.1016/S1470-2045(15)00065-0. Lancet Oncol. 2015. PMID: 26149879 No abstract available.
Clinical Pharmacology and Interplay of Immune Checkpoint Agents: A Yin-Yang Balance.
Geraud A, Gougis P, Vozy A, Anquetil C, Allenbach Y, Romano E, Funck-Brentano E, Moslehi JJ, Johnson DB, Salem JE. Geraud A, et al. Among authors: gougis p. Annu Rev Pharmacol Toxicol. 2021 Jan 6;61:85-112. doi: 10.1146/annurev-pharmtox-022820-093805. Epub 2020 Sep 1. Annu Rev Pharmacol Toxicol. 2021. PMID: 32871087 Review.
Definitions, outcomes, and management of hyperprogression in patients with non-small-cell lung cancer treated with immune checkpoint inhibitors.
Abbar B, De Castelbajac V, Gougis P, Assoun S, Pluvy J, Tesmoingt C, Théou-Anton N, Cazes A, Namour C, Khalil A, Gounant V, Besse B, Zalcman G, Brosseau S. Abbar B, et al. Among authors: gougis p. Lung Cancer. 2021 Feb;152:109-118. doi: 10.1016/j.lungcan.2020.12.026. Epub 2020 Dec 28. Lung Cancer. 2021. PMID: 33385736
Cytochrome P-450-mediated herb and food-drug interactions can be identified in cancer patients through patient self-reporting with a tablet application: results of a prospective observational study.
Gougis P, Géraud A, Hilmi M, Vozy A, Campedel L, Abbar B, Allio C, De Chatillon S, Portalier A, Lapray F, Choquet S, Spano JP, Reyal F, Mir O, Funck-Brentano C, Hamy AS. Gougis P, et al. ESMO Open. 2022 Dec;7(6):100650. doi: 10.1016/j.esmoop.2022.100650. Epub 2022 Dec 6. ESMO Open. 2022. PMID: 36493603 Free PMC article.
No Impact of Seasonality of Diagnoses on Baseline Tumor Immune Infiltration, Response to Treatment, and Prognosis in BC Patients Treated with NAC.
Grandal B, Aljehani A, Dumas E, Daoud E, Jochum F, Gougis P, Hotton J, Lemoine A, Michel S, Laas E, Laé M, Pierga JY, Alaoui Ismaili K, Lerebours F, Reyal F, Hamy AS. Grandal B, et al. Among authors: gougis p. Cancers (Basel). 2022 Jun 23;14(13):3080. doi: 10.3390/cancers14133080. Cancers (Basel). 2022. PMID: 35804852 Free PMC article.
46 results